Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (GAAP)
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Gross Profit
Gross Margin
R&D
R&D percent of Revenues
SG&A
SG&A percent of Revenues
Operating Income
Depreciation
Stock Based Compensation
Net Income
Net Income Margin
EPS³
2Q22
$589M
$184M
$168M
$941M
$498M
52.9%
$75M
8.0%
$368M
39.1%
$56M
$34M
$11M
$5M
0.5%
$0.01
BAUSCH + LOMB 1. Products with sales outside the United States impacted by F/X changes.
2Q21
$556M
$185M
$193M
$934M
$488M
52.2%
$71M
7.6%
$358M
38.3%
$58M
$34M
$15M
$44M
4.7%
$0.13
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
3. On a proforma basis after giving effect to the IPO.
Reported Change
6%
(1%)
(13%)
1%
2%
70 bps
(6%)
(3%)
(3%)
0%
(27%)
(89%)
Constant Currency²
11%
5%
(10%)
6%
7%
(8%)
(7%)
7%
6%
(27%)
(66%)
Organic Change²
11%
7%
(10%)
6%
9View entire presentation